Literature DB >> 22017440

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.

Laura M Snell1, Gloria H Y Lin, Ann J McPherson, Theo J Moraes, Tania H Watts.   

Abstract

GITR [glucocorticoid inducible tumor necrosis factor receptor (TNFR)-related protein] and 4-1BB are costimulatory TNFR family members that are expressed on regulatory and effector T cells as well as on other cells of the immune system. Here we discuss the role of GITR and 4-1BB on T cells during viral infections and in cancer immunotherapy. Systemic treatment with agonistic anti-4-1BB antibody leads to a number of immune system abnormalities, and clinical trials of anti-4-1BB have been terminated. However, other modes of 4-1BB ligation may be less toxic. To date, similar toxicities have not been reported for anti-GITR treatment of mice, although anti-GITR antibodies can exacerbate mouse autoimmune models. Intrinsic effects of GITR and 4-1BB on effector T cells appear to predominate over their effects on other cell types in some models. Despite their similarities in enhancing T-cell survival, 4-1BB and GITR are clearly not redundant, and both pathways are required for maximal CD8(+) T-cell responses and mouse survival following severe respiratory influenza infection. GITR uses TNFR-associated factor (TRAF) 2 and TRAF5, whereas 4-1BB recruits TRAF1 and TRAF2 to mediate survival signaling in T cells. The differential use of signaling adapters combined with their differential expression may explain the non-redundant roles of GITR and 4-1BB in the immune system.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017440     DOI: 10.1111/j.1600-065X.2011.01063.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  44 in total

1.  Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.

Authors:  Brian G Till; Oliver W Press
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 2.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Authors:  Payal Mittal; Rebecca Abblett; Joseph M Ryan; Adam T Hagymasi; Archibald Agyekum-Yamoah; Julia Svedova; Steven L Reiner; Marie-Clare St Rose; Matthew P Hanley; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2018-01-05       Impact factor: 5.422

4.  Characterization and Comparison of GITR Expression in Solid Tumors.

Authors:  Luis Vence; Samantha L Bucktrout; Irina Fernandez Curbelo; Jorge Blando; Bevin M Smith; Ashley E Mahne; John C Lin; Terrence Park; Edward Pascua; Tao Sai; Javier Chaparro-Riggers; Sumit K Subudhi; Jorge B Scutti; Maria G Higa; Hao Zhao; Shalini S Yadav; Anirban Maitra; Ignacio I Wistuba; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2019-07-29       Impact factor: 12.531

Review 5.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

6.  GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Authors:  David A Schaer; Sadna Budhu; Cailian Liu; Campbell Bryson; Nicole Malandro; Adam Cohen; Hong Zhong; Xia Yang; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-11       Impact factor: 11.151

7.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.

Authors:  Aruna Bitra; Tzanko Doukov; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

8.  CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence.

Authors:  Lichen Jing; Joshua T Schiffer; Tiana M Chong; Joseph J Bruckner; D Huw Davies; Phillip L Felgner; Juergen Haas; Anna Wald; G M G M Verjans; David M Koelle
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 9.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.